mechanisms drug inhibition signalling molecules 
emergence tumour-specific molecularly targeted agents signifies paradigm shift cancer therapy less reliance drugs non-discriminately kill tumour host cells although diversity targets giving rise new generation anticancer drugs expanded many challenges persist design effective treatment regimens complex interplay signal-transduction pathways complicates customization cancer treatments target single mechanisms however despite uncertainty precise dominant mechanisms action especially compounds targeting multiple gene products emerging agents producing significant therapeutic advances broad range human cancers 
